Management Programs for Oral Oncolytics Drive Adherence and Brand Loyalty

Management Programs for Oral Oncolytics Drive Adherence and Brand Loyalty

More than half of the cancer drugs newly approved in 2011 are administered orally.  Oral oncology medications make therapy more manageable and convenient for patients.  However, these therapies can pose potential challenges that are more commonly associated with chronic conditions.   Nonadherence and the possibility of interactions with other medications are issues requiring continued patient management.  Our research has found that:

  • There is a 37% nonadherence rate to oral cancer agents, compared to 31% for high blood pressure and heart disease or 29% for high cholesterol. 
  • There are hundreds of medications that may interact with oral cancer agents, potentially decreasing the efficacy or increasing the toxicity of the cancer medication.  In fact, oncologists may be unaware that their patient’s primary care physician prescribed potentially interacting medication, and this happens between 34% and 51% of the time.

Since oral oncology patients typically take their medications independently from a physician’s office or clinic, they benefit from the support of a specially trained nursing team who makes clinical assessments, monitors adverse reactions, and provides patient education and advocacy. 

That’s where our Therapeutic Resource Center for Oncology comes in.  More than 230 oncology personnel, including specialist pharmacists, focus on oncology patients and can quickly identify gaps in care, potentially harmful drug-drug interactions, and barriers to adherence. 

And, today, most brand teams would agree that well-managed patient support programs not only positively impact adherence, but are also an essential ingredient to building long-term patient engagement and loyalty. 

Bristol-Myers Squibb recognized the need for an experienced patient management program when it recently selected Accredo and CuraScript to provide Specialty Pharmacy patient support services for its oral oncology medication, SPRYCEL®. SPRYCEL is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CMS) in chronic phase. 

We’re pleased to join Bristol-Myers Squibb in this committed effort to the therapeutic success of SPRYCEL patients, and look forward to watching programs like this become an industry standard.